Analysis of Cancer Genomes for Personalized Immuno-therapy in Clinical Phase 1 Trial

Analysis of Cancer Genomes for Personalized Immuno-therapy in Clinical Phase 1 Trial

August 16, 2018

Address

727 E. Tyler St.
Tempe, AZ 85281

Location

Biodesign Institute, Auditorium

Date and Time

August 22, 2018, 3:30 pm (Length: 1 hour 0 minutes)

iCal Download

Hojoon Lee, PhD, Medical/Oncology, Stanford University School of Medicine

Antigen-driven processes are believed to be crucial to anticancer immune responses. Certain somatic mutations in cancer genomes result in amino acid alterations, which can generate tumor-specific immunogenic peptides called neoantigens. Most often these mutations are unique to individual patients, highlighting the need for personalized approaches to exploiting the interactions between T cells and mutation-derived tumor neoantigens. Streamlined and standardized methods to identify and characterize neoantigens profile / the immune cell populations are needed.